AINDEX
Markets

VolitionRx Limited (VNRX)

VNRXAMEXBiotechnology: In Vitro & In Vivo Diagnostic Substances

$0.1990

-0.0310 (-13.48%) today

Regular session, Nov 16, 11:08 AM ET

-14.13% 1D
Market cap
$7.17m
P/E
–
EPS, last 4 quarters
$-2.80
Dividend yield
–
Day range
$0.1900 to $0.2200
52-week range
$0.1564 to $7.73
Average volume
–
Previous close
$0.2300

Earnings

next estimate $-0.1900

Next report

Dec 2025

-25.0%

Mar 2026

-17.1%

Jun 2026

-14.7%

Sep 2026

+42.9%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$447.0k$985.0k$399.0k$1.61m
Gross profit$447.0k$985.0k$399.0k$1.61m
Operating income-$4.82m-$5.35m-$4.18m-$3.33m
Net income-$6.27m-$6.67m-$7.33m-$3.80m

Last four quarters: revenue $3.44m, margin -698.5%, free cash flow -$20.59m

News

8 latest

The company

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Sector
Health Care
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
AMEX
Region
Asia

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.